Dan Wermeling was a tenured professor at the University of Kentucky.  His principal areas of interest were early stage clinical drug development, drug delivery systems, analgesic delivery systems, and nasal drug delivery.  As an instructor he was responsible for courses entitled Introduction to Therapeutics (PY2) and FDA Regulation and Clinical Research Methods (graduate), and Clinical Reasoning (PY1).  Service obligations included formation and managing an Investigational Drug Service, formation of the clinical trials office, and creating a novel mobile pharmacy operation for initiating dispensing of Narcan to individuals at high risk of opioid overdose.

Dan was a consultant to the pharmaceutical industry in areas of clinical pharmacology, clinical trials, and drug delivery assessment.  He was principal investigator for Phase 1 compounds, new delivery systems and many trials of new analgesics.

Dan has an entrepreneurial spirit and has founded several start up companies during his career.  His most recent success was the commercialization of Nalscue brand of naloxone nasal spray.  He holds several patents and has had 10 INDs and 1 NDA.

His consulting career has included the legal system in the areas of medical malpractice and patent litigation.